Serum albumin (SA) is associated with inflammation and thrombosis, which are involved in acute aortic dissection (AAD). Our aim was to investigate the effect of SA level on survival in patients with AAD.
Introduction
Acute aortic dissection (AAD) is a rare life-threatening vascular emergency that is associated with high early and late morbidity and mortality rates. [1] The pre-hospital mortality rate of patients with untreated AAD is approximately 48.6%. [2] Dissections confined to the ascending aorta (type A) have worse short-term survival rates than those involving the descending aorta (type B). [1] Historically, the mortality rate was 1% to 2% per hour for the first 24 to 48 hours after symptom onset in ascending AAD. [3] The long-term outcomes of type B AAD are not necessarily better than those of type A AAD. The data from the International Registry of AAD show an in-hospital surgical mortality rate as high as 30% in type A AAD and 13% in type B. For type A patients treated by surgery who survive until hospital discharge, the mortality rates range from 4% to 48% at 1 year and 9% to 63% at 5 years. [4] [5] [6] [7] [8] The long-term mortality of surgically treated patients with type B AAD after discharge ranges from 4% to 44% at 1 year and 17% to 52% at 5 years, [4] [5] [6] 8] similar with those with type A AAD. Therefore, it is critically important to identify the high-risk AAD patients at an early phase.
AAD is associated with an inflammatory reaction, thrombosis, and oxidative stress, evidenced by a significant elevation in inflammatory markers, such as C-reactive protein (CRP), Ddimer, platelets (PLT) count, mean PLT volume to count ratio, and matrix metalloproteinase 9. [9] [10] [11] [12] [13] [14] However, a marker or a prognostic score that reflects multiple pathophysiological pathways may be superior to a single biomarker that reflects 1 pathophysiological pathway. [15] Serum albumin (SA), a stable protein in the human serum that is associated with systemic inflammation, thrombosis, and oxidative stress, is reported as a strong independent predictor of long-term mortality in cardiovascular disease. [16] Our previous study found that hypoalbuminemia was predictive for long-term mortality in type B AAD; however, that study was based on a small sample and did not identify the relation between SA and in-hospital mortality in type A and type B AAD. [17] Therefore, the primary goal of this study was to examine the hypothesis that low SA at admission is a good biomarker for early prediction of in-hospital mortality in patients with type A or B AAD.
Method

Study design
This was a single-center, retrospective cohort study, to evaluate the association between SA and the risk of in-hospital mortality in patients with AAD, regardless of type A or type B. The study was performed in accordance with the Helsinki Declaration and was approved by the Human Ethical Committee of West China Hospital of Sichuan University.
Study population
The study used data from the West China Hospital AAD database. This single-center database respectively included the data of all adults (≥18 years old) patients who were treated for AAD between January 2012 and December 2015. The inclusion criteria were:
(1) AAD presenting within 14 days of symptom onset, and (2) contrast-enhanced computed tomography confirming a dissected descending aorta containing both a true and false lumen.
The exclusion criteria were:
(1) pregnancy; (2) trauma-induced AAD; and (3) patients with infection, cancers, and other diseases related to the cardiovascular, urinary, endocrine, and immune systems.
Data collection and classifications
The clinical data of each patient with AAD was extracted from their clinical notes and charts available at the hospital. The database included demographic data, cardiovascular risk factors, medical history, results of blood tests at admission, inflammatory and thrombotic biomarkers, renal function, electrocardiographic, and computed tomography findings, details of medical treatment at the hospital, and the occurrence of in-hospital death. The Modification of Diet in Renal Disease equation was used to estimate the glomerular filtration rate (eGFR) in milliliters per minute per 1.73 m 2 . [18] The SA levels at admission were analyzed using an Architect c16000 analyzer (Abbott Diagnostics) and were categorized into 2 categories SA 34 g/L and SA >34 g/L.
Outcomes
The primary outcome was all-cause in-hospital mortality.
Statistical analysis
All statistical analysis was performed using IBM SPSS Statistics 21 software (IBM Corp., Armonk, NY). Patient characteristics were presented as frequencies and percentages for categorical variables and compared using the x 2 test or Fisher exact test. Normally distributed continuous variables were presented as mean and standard deviation and compared using Student t test while abnormally distributed variables were presented as median and 25th and 75th percentiles (Q1 and Q3, respectively) and compared using the Mann-Whitney U test. Kaplan-Meier curves were constructed and stratified according to different SA levels. In addition, a multivariable Cox regression analysis (forward: LR) was used to investigate the relationship between SA and inhospital mortality. We performed prespecified subgroup analyses to explore the effects of confounding factors on the association between SA and in-hospital mortality in AAD. Subgroup analyses were performed with the use of Kaplan-Meier curves and logrank tests. All tests were 2-sided and considered statistically significant at P <.05.
Results
Baseline patient characteristics
The initial cohort included 854 patients with AAD. We excluded 3 pregnant women, 34 patients with potentially confounding comorbidity (e.g., active infection and chronic inflammatory disease), 16 with trauma-induced AAD, and 37 with no SA levels at admission. Finally, 777 patients were included in the study. Of these, 305 (39.3%) patients had type A, and 472 (40.7%) had type B AAD. The mean age of the study cohort was 51 ± 13 years, 686 (88.3%) were males, and 129 (16.6%) died in hospital. The mean SA levels at admission were 34 ± 6 g/L with a median of 34 (30) (31) (32) (33) (34) (35) (36) (37) (38) 
The baseline characteristics of the study cohort are shown in Table 1 . Among the type A patients with AAD, 115 (37.7%) were hypoalbuminemic, defined as SA 34 g/L. Patients with Type A AAD and hypoalbuminemia were younger and had higher hemoglobin (Hb) and uric acid (UA) levels compared with those with SA >34 g/L. No differences were found in the other parameters between patients with and without hypoalbuminemia ( Table 1) . For patients with type B AAD, those with SA >34 g/L were comprised of more males, had higher rates of hypertension and smoking and increased left ventricular fractions, white blood cells (WBCs), UA, and Hb compared to those with hypoalbuminemia. The patients who had hypoalbuminemia had more PLT and higher indirect bilirubin and heart rate compared to those with SA >34 g/L. There were no differences in the other parameters between patients with and without hypoalbuminemia ( Table 1) .
SA and in-hospital mortality
In type, A AAD, the in-hospital mortality was higher in patients with hypoalbuminemia compared to those without (34.2% vs. 13.9%, P <.001; Fig. 1A ). Kaplan-Meier survival analysis showed that survival was significantly lower in patients with hypoalbuminemia compared to those without (log-rank x 2 = 14.71; P <.001; Fig. 1B ), irrespective of medication (log-rank x 2 = 10.77; P = .001; Fig. 1C ) or surgical therapy (log-rank x 2 = 4.34; P = .037; Fig. 1D ).
Among patients with type B AAD, those with hypoalbuminemia had higher in-hospital mortality rates than those without (7.9% vs 1.6%, P = 0.001; Fig. 2A ). Kaplan-Meier survival analysis indicated the cumulative survival rates of patients with hypoalbuminemia were lower compared to those without (logrank x 2 = 10.42; P = .001; Fig. 2B ), subgroup analysis showed a similar result in patients receiving medication (log-rank x 2 = 5.53; P = .019; Fig. 2C ) and endovascular therapy (log-rank x 2 = 4.07; P = .044; Fig. 2D ). None of the patients treated by surgery died.
The unadjusted hazard ratio (HR) of hypoalbuminemia for predicting in-hospital mortality in the univariate Cox regression model was 2.763 [95% confidence interval (CI), 1.599-4.776; P <.001) for type A and 4.976 (95% CI, 1.684-14.704; P = .004) Table 2 ). In type A AAD, subgroup analysis showed that hypoalbuminemia was independently associated with in-hospital mortality in subgroups with different ages and levels of systolic and diastolic blood pressure, heart rate, WBCs, PLTs, aspartate aminotransferase (AST), blood urea nitrogen, creatinine (Cr), and eGFR (Table 3 ). In type B AAD, hypoalbuminemia was also associated with the risk of in-hospital mortality in patients with different heart rates, AST, Cr, and eGFR (Table 4 ).
Discussion
The present study indicated that SA was independently associated with the in-hospital mortality of patient with AAD, irrespective of the different types and therapies. In addition, hypoalbuminemia was an independent predictor of in-hospital mortality among AAD patients with different inflammatory statuses and impaired renal function. Therefore, SA was a useful biomarker to stratify the high-risk patients with type A or B AAD. To the best of our knowledge, no studies had researched the prognostic value of SA in all types of AAD patients.
Prior studies had indicated that decreased SA levels were associated with an increased risk of cardiovascular mortality and other adverse outcomes. [16] Hypoalbuminemia was an independent predictor of in-hospital and long-term adverse outcomes of acute myocardial infarction (AMI), and was associated with the development of advanced heart failure in patients with AMI undergoing primary PCI. [19, 20] Furthermore, a reduction in SA over time, even 1 within the normal range, was also associated with an increased incidence of cardiovascular disease. [16] Plakht et al [21] found that SA at admission is an independent prognostic marker for long-term (up to 10 years) all-cause mortality in hospital survivors with AMI. In addition, reduced SA, even within the clinically normal range, is a strong biomarker of increased long-term mortality with a gradual "dose-response" association. In addition, Nakayama et al have found that a decreasing trend in SA level in patients with heart failure was correlated with a worse long-term prognosis, and that change of Table 1 Baseline characteristics of patients with acute aortic dissection. AST = aspartate aminotransferase, BUN = blood urea nitrogen, DB = direct bilirubin, DBP = diastolic blood pressure at admission, DM = diabetes mellitus, eGFR = estimated glomerular filtration rate, Hb = haemoglobin, IB = indirect bilirubin, LVEF = left ventricular ejection fraction, PLT = platelet count, SBP = systolic blood pressure at admission, TB = total bilirubin, WBC = white blood cell count. SA levels was also associated with changes in cachectic factors. [22] Therefore, SA may be a good marker to stratify high-risk patients with cardiovascular diseases. In Takeuchi et al's study, the mean albumin level of patients with AAD was significantly lower than that of healthy controls. Low SA levels and smoking, in addition to hypertension, are significantly associated with AAD. [23] Our previous study showed that hypoalbuminemia was present in 47% of patients with type B AAD and that it was associated with long-term mortality. [17] However, the study was based on a small sample and we did not investigate the relationship between SA and inhospital outcomes in patients with type A AAD. [17] Furthermore, in subgroup analysis according to different therapies, inflammatory marker (WBC) levels, and renal function, hypoalbuminemia was also associated with an increased risk of in-hospital mortality in patients with type A or B AAD. Subgroup analysis also showed that the association between SA and the risk of in-hospital mortality was not influenced by potential confounding factors. Therefore, SA was a useful biomarker for early risk stratification of patients with AAD. The mechanisms underlying the association between reduced SA and mortality in patients with AAD are not clear; however, several explanations could be considered. First, the decreased synthesis and increased catabolism of SA in relation to Table 3 Subgroup analysis of Kaplan-Meier survival analysis of the association between hypoalbuminaemia and in-hospital mortality of patients with type A acute aortic dissection. AAD = acute aortic dissection, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CR = Creatinine, DB = direct bilirubin, DBP = diastolic blood pressure at admission, eGFR = estimated glomerular filtration rate, IB = Indirect bilirubin, PLT = platelet count, SA = serum albumin, SBP = systolic blood pressure at admission, UA = uric acid, WBC = white blood cell count. AAD = acute aortic dissection, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CR = Creatinine, DB = direct bilirubin, DBP = diastolic blood pressure at admission, eGFR = estimated glomerular filtration rate, IB = Indirect bilirubin, PLT = platelet count, SA = serum albumin, SBP = systolic blood pressure at admission, UA = uric acid, WBC = white blood cell count.
Gao et al. Medicine (2019) 98:6 www.md-journal.com inflammation. [24] Inflammation plays an important and crucial role along the entire continuum of AAD pathophysiology, and the severity of inflammation has been shown to be associated with rupture of aortic dissection. [25] Inflammatory markers, such as CRP [26] and WBCs, [10, 27] have also been shown as predictors of short and long-term mortality in patients with AAD. The SA levels of patients with type B AAD who died were lower than those of survivors, and low SA was also associated with inhospital adverse outcomes and long-term mortality. [17] Second, SA is a significant inhibitor of PLT activation and aggregation and a mediator of PLT-induced coronary artery disease. Therefore, reduced SA levels could be associated with an increased risk for thrombotic events related to increased PLT activation and aggregation. [28] PLTs play an important role in thrombosis, which is involved in AAD. [9] The thrombus status is associated with the severity of AAD and could reflect the prognosis at an early phase. [9] Some thrombus biomarkers, including D-dimer [29, 30] and fibrinogen, [31] were reported to be useful for stratification of high-risk patients with AAD. In previous studies, the mean PLT volume to count ratio, [12] PLT count, [14] and markers of PLT activity, were independent predictors of mortality in patients with type A AAD. Therefore, low SA was associated with increased risks of mortality in association with PLT activation and thrombosis in AAD. Finally, oxidative stress is also involved in AAD patients with reduced SA. [32] Increased oxidative stress was reported to be associated with deleterious long-term outcomes in patients following AMI. [33] Thus, 1 possible explanation for why hypoalbuminemia is associated with in-hospital mortality after AAD is the antioxidant activity of albumin. In our previous study, no sufficient evidence was found to support the concept that decreased nutritional intake and liver and renal dysfunction were associated with decreased SA in AAD patients. [16, 17] Therefore, low SA most frequently arises from the inflammatory response, oxidative stress, and PLT activity. In the present study, low SA was predictive of in-hospital mortality in AAD, regardless of inflammatory status and PLT activity. SA may be a biomarker that reflects multiple pathophysiological processes that are involved in the severity of AAD.
Limitations
This study has several limitations that should be considered when interpreting its findings. First, the present study was a singlecenter, respective observational study. A prospective, large-scale multicenter study is needed to confirm our conclusions. Second, some inflammatory and thrombotic biomarkers, such as CRP and D-dimer, could not be detected, and in-hospital adverse outcomes were not collected in the present study. We could not analyze the relationship between some inflammatory and thrombotic biomarkers or in-hospital adverse outcomes and SA. Third, we did not analyze SA variation at different time points during hospitalization.
Future directions
For future research, several aspects should be considered. First, the relationship between AAD with some other inflammatory and thrombotic biomarkers or combination of these indicators could be analyzed. Second, articles about the molecular and genetic mechanisms of SA in the progress of pathophysiology of AAD formation and development are needed directly. Third, whether the intervention for the hypoalbuminemia AAD patients could improve the prognosis of these patients effectively need to be verified.
Conclusions
The results from this study indicate that reduced SA is associated with a high risk of in-hospital mortality in patients with AAD, irrespective of confounding factors. SA was a useful biomarker for early stratification of high-risk patients with AAD. 
Author contributions
